CAPR vs FBYD Comparison

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has four operating segments, Falcon's Creative Group, PDP, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.